Contineum Therapeutics (CTNM) Liabilities and Shareholders Equity (2023 - 2026)

Contineum Therapeutics' Liabilities and Shareholders Equity history runs 4 years deep, the most recent figure standing at $261.3 million for Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 31.82% year-over-year to $261.3 million in Q1 2026; TTM through Mar 2026 was $911.7 million, a 7.45% increase from a year earlier, with the FY2025 full-year figure at $276.6 million, up 29.97% from the prior year.
• Liabilities and Shareholders Equity slipped to $261.3 million in Q1 2026 per CTNM's latest filing, from $276.6 million in the prior quarter.
• Across five years, Liabilities and Shareholders Equity topped out at $276.6 million in Q4 2025 and bottomed at $123.6 million in Q1 2024.
• The 4-year median for Liabilities and Shareholders Equity is $205.6 million (2024), against an average of $201.4 million.
• Across the five-year window, Liabilities and Shareholders Equity surged 63.24% in 2024 and fell 17.38% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $130.4 million in 2023, then soared by 63.24% to $212.8 million in 2024, then increased by 29.97% to $276.6 million in 2025, then dropped by 5.53% to $261.3 million in 2026.
• Per Business Quant, the three latest CTNM Liabilities and Shareholders Equity figures stand at $261.3 million (Q1 2026), $276.6 million (Q4 2025), and $190.8 million (Q3 2025).